How pharma is charting a greener path to growth 

The conversation around environmental sustainability in the pharma industry is now expanding beyond the traditional boundaries of the compliance department. For years, the life sciences sector treated sustainability largely as a peripheral function, focusing primarily on meeting local waste management rules, running safety checklists, and fulfilling regulatory mandates. Today, industry leaders are viewing it as a core business strategy that is central to competitiveness, risk management, operational resilience, brand reputation, and long-term value creation 

This changing industry outlook is becoming increasingly important as the sector begins to confront the scale of its environmental footprint. Making medicines is far more resourceintensive than most people realise. Data from a recent study published in The Lancet Planetary Health shows that the pharma sector’s direct emissions intensity is around 60 per cent higher than healthcare services, and nearly 80 per cent higher when total emissions are considered. At the same time, the industry’s greenhouse gas footprint is growing faster than both healthcare services and the global average. 

The urgency around this challenge is only compounding as the industry continues to expand. The global pharma market is on track to cross $2.8 trillion by 2033, while India’s pharma sector alone is projected to surpass $130 billion by 2030. Therefore, the sector has the responsibility to scale commercial growth in a way that also reduces its environmental footprint and preserves the ecosystems that sustain both manufacturing operations and long-term public health. 

Many leading pharma companies and contract research, development, and manufacturing organisations (CRDMOs) are responding proactively by accelerating the adoption of green technologies to align with changing client and regulatory expectations. Manufacturers are actively seeking greener alternatives for hazardous reagents, solvents, and chemicals. By overcoming traditional technical barriers and embedding the core principles of reducing, reusing, and recycling directly into waste management loops, labs and manufacturing facilities are establishing clear actions for carbon emission reduction. This includes department-level self-assessments of carbon dioxide output and the integration of rigorous environment, occupational health, safety, and sustainability (EHSS) management systems, which builds deeper trust with stakeholders, including governments, communities, partners, and employees. 

Beyond materials and chemistry, energy utilisation has emerged as a critical area where sustainability directly dictates business performance. Because pharma manufacturing plants run on continuous, 24-hour operating cycles, they are acutely vulnerable to rising power tariffs and grid instability. However, by investing in captive power capabilities, particularly green energy assets, companies are securing both supply continuity and cost insulation. This establishes a clear, undeniable business case: sustainability is not merely an exercise in corporate altruism, but a powerful lever for profitability. Across the broader pharma value chain, locking in long-term renewable energy contracts allows manufacturers to mitigate emissions while simultaneously stabilising operating expenditures. This operational predictability is what ultimately protects production timelines, safeguards supply continuity and stabilises pricing. 

A similar business impact is playing out in the realm of water management, where resource conservation has rapidly evolved into a high-stakes risk-management issue. Highpurity water is the absolute lifeblood of medicine formulation and sterile equipment cleaning; yet a significant portion of global manufacturing capacity is concentrated in regions already grappling with acute water scarcity. At Syngene, we recognise that resource depletion poses a risk to operational continuity. We are investing in zero-liquid discharge (ZLD) technologies and closed-loop water purification infrastructure to enhance water security and sustainability across our operations. By recycling and reusing industrial wastewater on-site, these systems significantly reduce dependence on municipal freshwater sources, helping ensure uninterrupted manufacturing operations even during periods of water scarcity. 

As organisations globally realise that sustainability yields broader business resilience, they are looking beyond their own factory walls to audit their entire value chain. Global pharma innovators are leading this charge, committing to greenhouse gas reductions that explicitly include their supplier networks under Science Based Targets initiative (SBTi) Scope 3 mandates. Because indirect emissions from raw material sourcing, outsourced manufacturing, and logistics often represent the lion’s share of a pharma multinational’s total carbon footprint, environmental transparency is no longer an optional procurement metric. Instead, sustainability has become a decisive factor in vendor selection, weighted alongside traditional benchmarks like scientific capability, regulatory track records, delivery reliability, and cost. This paradigm shift creates a powerful cascading effect: suppliers must adopt rigorous, sustainable operating models simply to qualify as preferred partners for global drug innovators. 

This rigorous corporate scrutiny is being mirrored closely in the capital markets, where institutional investors have stopped treating environmental reporting as an optional footnote in the annual report. Today, climate risks, resource dependencies, and carbon liabilities are analysed as leading indicators of a company’s longterm financial viability. To command premium valuations and optimise their cost of capital, pharma boards are bringing sustainability directly into corporate governance. This capital market pressure is accelerating the adoption of strict, auditable reporting frameworks, ensuring that environmental performance data is processed with the same accuracy, granularity, and trustworthiness as traditional financial accounting. 

The Indian pharma sector has been at the forefront of the sustainability transition, adopting best practices to align its production capacity with global eco-standards. This green transition is creating competitive advantage for India’s contract manufacturing sector, which has developed a global reputation for scientific talent, scale, and cost efficiencies. By embedding sustainable engineering, transparent life-cycle tracking, and low-emission production into their core value proposition, Indian contract manufacturers are strengthening their positioning, transitioning from service providers to long-term strategic partners for global innovators. Over the coming decade, leadership in the life sciences world will be redefined by the ability to scale responsibly through resilient, circular operations. For India’s pharma ecosystem, this transformation offers an opportunity to move beyond its identity as a high-volume manufacturing hub and emerge as a global model for sustainable, highvalue pharma production.